Ferric Carboxymaltose [Ferinject]

Colon Cancer

Helsinki University Central HospitalN/ADormant

D

28/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 15/ 100
Competitive Position: 65/ 100

Competitive context

128 Active assets in the Colon Cancer cohort.

Asset / Sponsor	Phase	Rating
FLUOROURACILUM Akeso	Phase 4	BB
Calcium folinate pentahydrate Akeso	Phase 3	BB
Eloxatin Sun Yat-sen University	Phase 3	BB
Irinotecan SCRI Development Innovations, LLC	Phase 3	BB
MACROGOLS University Medical Center Ho Chi Minh City (UMC)	Phase 4	BB

View all 50 →

Same molecule, other indications

Ferric Carboxymaltose [Ferinject] is also rated in:

Iron DeficienciesDormant

A

Indicative ·

80 / 100

anemiaDormant

BBB

Indicative ·

75 / 100

colorectal neoplasmDormant

BBB

Indicative ·

73 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.